Rybelsus, 糖尿病药物, 在2型糖尿病患者中, 将重大心脏病风险降低14%, Rybelsus, a diabetes drug, cuts major heart risks by 14% in type 2 diabetes patients, trial shows.

Novo Nordisk的糖尿病药物Rybelsus将患2型糖尿病和心脏病或肾病的病人患重大心血管疾病的风险降低14%。 Novo Nordisk's diabetes medication Rybelsus reduced the risk of major cardiovascular events by 14% in patients with type 2 diabetes and heart or kidney disease, according to a recent trial. 该药物经过四年测试,没有显示出新的安全顾虑,并具有恶心和腹泻等常见副作用。 The drug, which was tested over four years, showed no new safety concerns and had common side effects like nausea and diarrhea. 诺沃·诺迪斯克已申请美国和欧盟扩大批准,以包括心脏保护福利。 Novo Nordisk has applied for expanded approval in the U.S. and EU to include heart protection benefits.